PAR & MPS, page-2

Hi Mozzarc,

Thanks for posting this - very interesting.

But seriously, we need to be a bit realistic here.

IMO it's totally unrealistic to build a business plan, or construct an investment case, predicated on taking a freely available out-of-patent drug that's been around for close to half a century, and which currently sells for a couple of hundred dollars, repurposing it, getting some patent protection, and then selling the same drug for between $2,000 and $50,000 (!!!) per course, depending on the disease it's being used to treat.
I really hope this isn't the business plan!

I'm still fairly confident that PAR will prove a profitable investment, but I certainly don't see it as a new CSL.

Just my opinion as usual